Drugs / Boostrix Polio
Boostrix Polio
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 33 trials · 2 met primary | ||||||
| Phase 3 | NCT01245049 | Apr 2011 → Mar 2012 | diphtheria, poliomyelitis, tetanus | GlaxoSmithKline | Completed | Met primary |
| Phase 3 | NCT00871000 | Apr → Nov 2009 | diphtheria, poliomyelitis, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00426361 | Feb 2007 → Mar 2008 | human papilloma virus infection | GlaxoSmithKline | Completed | Met primary |
| Phase 42 trials | ||||||
| Phase 4 | NCT00635128 | Feb → Jul 2008 | diphtheria, poliomyelitis, tetanus | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 4 | NCT00514059 | Apr → Jun 2007 | diphtheria, pertussis, poliomyelitis, tetanus | Norwegian Institute of Public Health | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Boostrix-Polio | “received a single booster dose of the Boostrix™-Polio vaccine” NCT00635128 ↗ |
| Known as | Boostrix IPV | “poliomyelitis vaccine (dTpa-IPV; Boostrix™ IPV).” PMID 20448468 ↗ Jul 20101“dTap-IPVB vaccine (Boostrix-IPV, GSK)” PMID 29576304 ↗ Mar 2018 |
| Known as | BoostrixTM Polio | “poliomyelitis; BoostrixTM Polio, GlaxoSmithKline)booster” PMID 20448468 ↗ Jul 2010 |
| Known as | dTap-IPVB | “dTap-IPVB vaccine (Boostrix-IPV, GSK)” PMID 29576304 ↗ Mar 2018 |
| Modality | Vaccine | “dTpa-IPV vaccine” NCT00426361 ↗ |
| Route | Intramuscular | “One dose of vaccine administered intramuscularly” NCT00426361 ↗ |